Eli Lilly And Co (NYSE:LLY) issued its quarterly earnings data on Thursday. The company reported $1.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.58 by $0.31, MarketWatch Earnings reports. The business had revenue of $5.50 billion for the quarter, compared to the consensus estimate of $5.77 billion. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The company’s quarterly revenue was down 2.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.50 EPS. Eli Lilly And Co updated its FY 2020
Pre-Market guidance to 7.20-7.40 EPS and its FY20 guidance to $7.20-$7.40 EPS.
Shares of Eli Lilly And Co stock opened at $150.29 on Friday. The stock has a market cap of $143.74 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.32 and a beta of 0.26. The firm’s 50-day moving average is $160.88 and its 200 day moving average is $148.62. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $170.75. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, August 13th. Eli Lilly And Co’s payout ratio is 49.01%.
A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Guggenheim raised shares of Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price objective on the stock in a research report on Tuesday, June 16th. Mizuho upped their target price on shares of Eli Lilly And Co from $155.00 to $164.00 and gave the stock a “neutral” rating in a research report on Monday, June 29th. Morgan Stanley downgraded shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research report on Sunday, April 19th. Finally, Zacks Investment Research reduced their target price on shares of Eli Lilly And Co to $156.00 in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $168.58.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Correction
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.